Streetbeat News

AURA

Aura Biosciences, Inc.

https://www.aurabiosciences.com

Industry

Biotechnology

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Open

10.04

Mkt cap

470M

Volume

280K

High

10.16

P/E Ratio

-5.29

52-wk high

12.38

Low

9.42

Div yield

N/A

52-wk low

6.63

HC Wainwright & Co. has reiterated its Buy rating on Aura Biosciences, maintaining a price target of $21. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 10:25 am

Aura Biosciences reported promising Phase 2 results for its eye cancer treatment, bel-sar, showing an 80% tumor control rate and high visual acuity preservation. The treatment has a favorable safety profile and has received FDA agreement for a Phase 3 trial. Aura's stock rose 6.39% following the news.

Portfolio Pulse from Vandana Singh

September 12, 2024 | 3:40 pm

Aura Biosciences shares rose following the announcement of positive Phase 2 study results for bel-sar, a treatment for early-stage choroidal melanoma.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:43 am

Aura Biosciences reported positive Phase 2 results for Bel-sar as a first-line treatment for early-stage choroidal melanoma, showing an 80% tumor control rate, 90% visual acuity preservation, and a highly favorable safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:33 am

JMP Securities has reiterated its Market Outperform rating for Aura Biosciences, maintaining a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 2:33 pm

Aura Biosciences will present Phase 2 study data on bel-sar for treating early-stage choroidal melanoma at the Retina Society Annual Meeting in 2024.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 8:07 pm

Aura Biosciences reported a Q2 2024 GAAP EPS of $(0.41), beating the estimate of $(0.46). The company has cash, cash equivalents, and marketable securities totaling $187.4 million, which are expected to fund operations into the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:28 pm

Aura Biosciences shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 4:14 pm

HC Wainwright & Co. has initiated coverage on Aura Biosciences (NASDAQ:AURA) with a Buy rating and a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:39 am

Aura Biosciences (NASDAQ:AURA) reported Q4 earnings, beating estimates with an EPS of $-0.5 against an expected $-1.82 but with no change in revenue from the previous year. The company had previously seen a 10% share price increase following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.